Literature DB >> 32785663

Plasma Dehydroepiandrosterone Sulfate and Cardiovascular Disease Risk in Older Men and Women.

Xiaoming Jia1, Caroline Sun1, Olive Tang2, Ivan Gorlov1, Vijay Nambi1,3, Salim S Virani1,3, Dennis T Villareal1, George E Taffet1, Bing Yu4, Jan Bressler4, Eric Boerwinkle4, B Gwen Windham5, James A de Lemos6, Kunihiro Matsushita2, Elizabeth Selvin2, Erin D Michos7, Ron C Hoogeveen1, Christie M Ballantyne1.   

Abstract

CONTEXT: Lower dehydroepiandrosterone-sulfate (DHEA-S) levels have been inconsistently associated with coronary heart disease (CHD) and mortality. Data are limited for heart failure (HF) and association between DHEA-S change and events.
OBJECTIVE: Assess associations between low DHEA-S/DHEA-S change and incident HF hospitalization, CHD, and mortality in older adults.
DESIGN: DHEA-S was measured in stored plasma from visits 4 (1996-1998) and 5 (2011-2013) of the Atherosclerosis Risk in Communities study. Follow-up for incident events: 18 years for DHEA-S level; 5.5 years for DHEA-S change.
SETTING: General community. PARTICIPANTS: Individuals without prevalent cardiovascular disease (n = 8143, mean age 63 years). MAIN OUTCOME MEASURE: Associations between DHEA-S and incident HF hospitalization, CHD, or mortality; associations between 15-year change in DHEA-S (n = 3706) and cardiovascular events.
RESULTS: DHEA-S below the 15th sex-specific percentile of the study population (men: 55.4 µg/dL; women: 27.4 µg/dL) was associated with increased HF hospitalization (men: hazard ratio [HR] 1.30, 95% confidence interval [CI], 1.07-1.58; women: HR 1.42, 95% CI, 1.13-1.79); DHEA-S below the 25th sex-specific percentile (men: 70.0 µg/dL; women: 37.1 µg/dL) was associated with increased death (men: HR 1.12, 95% CI, 1.01-1.25; women: HR 1.19, 95% CI, 1.03-1.37). In men, but not women, greater percentage decrease in DHEA-S was associated with increased HF hospitalization (HR 1.94, 95% CI, 1.11-3.39). Low DHEA-S and change in DHEA-S were not associated with incident CHD.
CONCLUSIONS: Low DHEA-S is associated with increased risk for HF and mortality but not CHD. Further investigation is warranted to evaluate mechanisms underlying these associations. © Endocrine Society 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  DHEA-S; aging; heart failure; mortality

Mesh:

Substances:

Year:  2020        PMID: 32785663      PMCID: PMC7526732          DOI: 10.1210/clinem/dgaa518

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  59 in total

Review 1.  Is dehydroepiandrosterone a hormone?

Authors:  F Labrie; V Luu-The; A Bélanger; S-X Lin; J Simard; G Pelletier; C Labrie
Journal:  J Endocrinol       Date:  2005-11       Impact factor: 4.286

2.  Extracellular chromatin is an important mediator of ischemic stroke in mice.

Authors:  Simon F De Meyer; Georgette L Suidan; Tobias A Fuchs; Marc Monestier; Denisa D Wagner
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-05-24       Impact factor: 8.311

3.  Longitudinal changes in dehydroepiandrosterone concentrations in men and women.

Authors:  A N Nafziger; S J Bowlin; P L Jenkins; T A Pearson
Journal:  J Lab Clin Med       Date:  1998-04

4.  DHEA in elderly women and DHEA or testosterone in elderly men.

Authors:  K Sreekumaran Nair; Robert A Rizza; Peter O'Brien; Ketan Dhatariya; Kevin R Short; Ajay Nehra; Janet L Vittone; George G Klee; Ananda Basu; Rita Basu; Claudio Cobelli; Gianna Toffolo; Chiara Dalla Man; Donald J Tindall; L Joseph Melton; Glenn E Smith; Sundeep Khosla; Michael D Jensen
Journal:  N Engl J Med       Date:  2006-10-19       Impact factor: 91.245

5.  Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study.

Authors:  Justin T Saunders; Vijay Nambi; James A de Lemos; Lloyd E Chambless; Salim S Virani; Eric Boerwinkle; Ron C Hoogeveen; Xiaoxi Liu; Brad C Astor; Thomas H Mosley; Aaron R Folsom; Gerardo Heiss; Josef Coresh; Christie M Ballantyne
Journal:  Circulation       Date:  2011-03-21       Impact factor: 29.690

6.  Apoptotic release of histones from nucleosomes.

Authors:  Dongcheng Wu; Alistair Ingram; Jill H Lahti; Brie Mazza; Jose Grenet; Anil Kapoor; Lieqi Liu; Vincent J Kidd; Damu Tang
Journal:  J Biol Chem       Date:  2002-01-25       Impact factor: 5.157

7.  Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue.

Authors:  E E Baulieu; G Thomas; S Legrain; N Lahlou; M Roger; B Debuire; V Faucounau; L Girard; M P Hervy; F Latour; M C Leaud; A Mokrane; H Pitti-Ferrandi; C Trivalle; O de Lacharrière; S Nouveau; B Rakoto-Arison; J C Souberbielle; J Raison; Y Le Bouc; A Raynaud; X Girerd; F Forette
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-11       Impact factor: 11.205

8.  Agouti-related protein antagonizes glucocorticoid production induced through melanocortin 4 receptor activation in bovine adrenal cells: a possible autocrine control.

Authors:  Mabrouka Doghman; Philippe Delagrange; Antonine Blondet; Marie-Claude Berthelon; Philippe Durand; Danielle Naville; Martine Bégeot
Journal:  Endocrinology       Date:  2003-10-30       Impact factor: 4.736

9.  Dehydroepiandrosterone reverses systemic vascular remodeling through the inhibition of the Akt/GSK3-{beta}/NFAT axis.

Authors:  Sébastien Bonnet; Roxane Paulin; Gopinath Sutendra; Peter Dromparis; Melanie Roy; Kristalee O Watson; Jayan Nagendran; Alois Haromy; Jason R B Dyck; Evangelos D Michelakis
Journal:  Circulation       Date:  2009-09-14       Impact factor: 29.690

10.  Prospective Study of Endogenous Hormones and Incidence of Venous Thromboembolism: The Atherosclerosis Risk in Communities Study.

Authors:  Nicholas S Roetker; Richard F MacLehose; Ron C Hoogeveen; Christie M Ballantyne; Saonli Basu; Mary Cushman; Aaron R Folsom
Journal:  Thromb Haemost       Date:  2018-10-08       Impact factor: 5.249

View more
  6 in total

1.  Dehydroepiandrosterone inhibits vascular proliferation and inflammation by modulating the miR-486a-3p/NLRP3 axis.

Authors:  Manli Zhang; Manna Zhang; Wenli Wang; Hui Chen; Xia Wang; Kun Zhao; Ze Li; Jiangqing Xu; Fei Tong
Journal:  Am J Transl Res       Date:  2022-09-15       Impact factor: 3.940

2.  Dehydroepiandrosterone in fibrotic interstitial lung disease: a translational study.

Authors:  Sabina A Guler; Carlos Machahua; Thomas K Geiser; Gregor Kocher; Thomas M Marti; Benjamin Tan; Verdiana Trappetti; Christopher J Ryerson; Manuela Funke-Chambour
Journal:  Respir Res       Date:  2022-06-08

3.  Associations between blood sex steroid concentrations and risk of major adverse cardiovascular events in healthy older women in Australia: a prospective cohort substudy of the ASPREE trial.

Authors:  Rakibul M Islam; Robin J Bell; David J Handelsman; John J McNeil; Mark R Nelson; Christopher M Reid; Andrew M Tonkin; Rory S Wolfe; Robyn L Woods; Susan R Davis
Journal:  Lancet Healthy Longev       Date:  2022-02-07

4.  Identification of vital modules and genes associated with heart failure based on weighted gene coexpression network analysis.

Authors:  Weikang Bian; Zhicheng Wang; Xiaobo Li; Xiao-Xin Jiang; Hongsong Zhang; Zhizhong Liu; Dai-Min Zhang
Journal:  ESC Heart Fail       Date:  2022-02-06

5.  Low Serum Dehydroepiandrosterone and Dehydroepiandrosterone Sulfate Are Associated With Coronary Heart Disease in Men With Type 2 Diabetes Mellitus.

Authors:  Xinxin Zhang; Jinfeng Xiao; Tong Liu; Qing He; Jingqiu Cui; Shaofang Tang; Xin Li; Ming Liu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-27       Impact factor: 6.055

6.  Circulating sex hormones and risk of atrial fibrillation: A systematic review and meta-analysis.

Authors:  Peng Hu; Jun Huang; Yi Lu; Murui Zheng; Haiyi Li; Xueru Duan; Hai Deng; Wenjing Zhao; Xudong Liu
Journal:  Front Cardiovasc Med       Date:  2022-08-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.